Organogenesis Holdings Stock (NASDAQ: ORGO)

Organogenesis Holdings

Organogenesis Hldgs

Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.

Warner Bros. Discovery

News

Intraday Update

Markets

Movers

Trading Ideas

ASTS

CRCL

ETOR

JOBY

MTSR

NBIS

NVTS

ORGO

RERE

VSAT

Warner Bros. Discovery, Metsera, eToro Group And Other Big Stocks Moving Higher On Monday

movers image

AMPS

CAVA

DAVE

HNST

JBLU

JTAI

NTRA

RIVN

RKLB

SPOT

TSEM

Paymentus Posts Better-Than-Expected Earnings, Joins Dave, Honest Company, Natera, CAVA Group And Other Big Stocks Moving Higher On Wednesday

Pre-Market Outlook

CDNA

HSHP

JFIN

LSEA

QRTEB

CareDx, JD.com And Other Big Stocks Moving Lower In Tuesday&#39;s Pre-Market Session

Organogenesis Holdings Inc

Health Care

Press Releases

General

Organogenesis Reports Positive Interim Analysis of Second Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis

Organogenesis Holdings Inc. Announces $130 Million Private Placement Offering of Series A Convertible Preferred Stock

Earnings

Organogenesis Holdings Inc. Reports Third Quarter 2024 Financial Results

Financing

Organogenesis Commends Final LCDs

Organogenesis Expands Manufacturing Capacity to Support Future Growth

Organogenesis Holdings Inc. to Report Fourth Quarter of Fiscal Year 2024 Financial Results on February 27, 2025

Organogenesis Holdings Inc. Reports Fourth Quarter 2024 Financial Results

Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2025 Financial Results on May 8, 2025

Organogenesis Supports CMS' Local Coverage Determination Implementation Delay to Review Coverage Policies to Maintain Patient Access with High Quality Evidence of Effectiveness

Organogenesis Holdings Inc. Reports First Quarter 2025 Financial Results

Absci

Abivax

aTyr Pharma

Aura Biosciences

Benitec Biopharma

Celcuity

COMPASS Pathways Plc - American Depository Shares

Compass Pathways

Erasca

Humacyte

ITeos Therapeutics

Inventiva S.A. - American Depository Shares

Inventiva

Kamada

Mereo BioPharma Group plc - American Depositary Shares

Mereo BioPharma Group

Myriad Genetics

Oruka Therapeutics

Precigen

PureTech Health plc - American Depositary Shares

PureTech Health

Regenxbio

Rezolute

Solid Biosciences

Savara

Tectonic Therapeutic, Inc. - Common Stock

Tectonic Therapeutic

Tourmaline Bio

Vigil Neuroscience

Zenas BioPharma

Morgan Stanley

Lake Street

Cantor Fitzgerald

BTIG

Comments

Organogenesis Holdings

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell